悉尼大学领导的bienco财团已从澳大利亚政府获得3500万美元，用于将其在角膜失明治疗方面的世界领先研究商业化。 bienco财团开发的人工角膜标本。 图片来源：悉尼大学stefanie zingsheim澳大利亚政府已向bienco授予3500万美元，bienco是一个领导角膜失明研究的研究小组，估计全球有2300万人患有角膜失明。 bienco是世界上第一个由悉尼大学、卧龙岗大学、墨尔本大学、昆士兰科技大学、澳大利亚眼科研究中心和新南威尔士州器官组织捐赠服务中心的临床、科学和治理专家组成的联盟。 它正在开发一种生物工程角膜替代组织，将已故捐赠者慷慨捐赠的细胞和组织结合起来。 角膜疾病是第三种最常见的失明形式，超过1000万人在等待角膜移植。 gerard sutton教授。 图片来源：悉尼大学stefanie zingsheim项目负责人悉尼大学gerard sutton教授表示，这种疾病对人们的生活有着深远的影响，并给卫生系统带来了巨大的代价。 “bienco是由这组澳大利亚研究人员于2021年推出的，旨在创造角膜，防止世界各地的人们不必要地失明。 多亏了我们的合作伙伴，我们能够快速开发出角膜失明的单词优先解决方案。 “我们相信这是澳大利亚历史上最大的一笔眼科研究拨款，”悉尼大学拯救视力研究所角膜专家、新南威尔士大学组织库前医学主任萨顿教授说。 卧龙岗大学备受尊敬的创新者、教育家和健康技术前沿科学家gordonwallace教授说：“这使我们成为全球生物工程组织供应商，并使我们对我们工作的重要性和bienco团队所取得的进步感到谦卑。 “每年有2000多名澳大利亚人需要角膜组织移植来恢复视力。 其中许多是原住民和托雷斯海峡岛民。 “目前，这些移植依赖于死者捐献的组织。 发展中国家，包括非洲和东南亚的许多国家，由于缺乏组织库，角膜长期短缺。 cera角膜研究负责人mark daniell教授说：“bienco的基础工作已经在创造下一代生物工程材料方面取得了重大进展，这将大大减少对捐赠组织的需求，提高患者获得护理的速度和质量。”。 由damienharkin教授领导的qut-bienco节点将在分离、培养和验证供体角膜细胞的方法方面提供关键的专业知识。 “目前，全球每70个需要角膜移植的人中只有一个可以接受角膜移植。 哈金教授说：“通过实验室培养，我们估计一个供体角膜可以为30人提供治疗。”。 图片来源：悉尼大学器官和组织捐赠服务部总经理stefanie zingsheim表示，严重的视力障碍和失明会产生深远影响，包括生活质量下降、医疗成本、长期护理成本以及生产力下降造成的成本。 费舍尔女士说：“恢复视力不仅有利于个人，也有利于他们的家庭和社区。”。 “这让他们能够回到他们喜欢的工作、学习和社区活动中去。 它还减轻了照顾他们的人的负担。 bienco生物工程产品将在一定程度上通过创造更好的患者结果来创造健康经济效益。 gregqiao教授将领导墨尔本大学node专注于该项目的合成基质，他说：“我们的最终目标是开发从一个捐赠者的组织中生产许多移植物的技术，以帮助缓解全球供体角膜短缺的问题。”。 部长马克·巴特勒今天宣布了这项拨款，他说：“这项设施是朝着确保为那些需要帮助的人提供帮助迈出的重要一步。”。 这些革命性的治疗方法再次证明，澳大利亚的医学研究人员是世界上最好的。 悉尼大学副校长兼校长奥教授补充说，这笔资金是对悉尼大学具有全球影响力的转化研究战略的认可。 “角膜失明是一个全球性的挑战，尤其是对我们在东南亚的近邻来说。 斯科特教授说：“这笔mrff赠款是对我们致力于解决世界上一些最大问题并为共同利益做出贡献的研究的认可，这是我们2032年战略的基础。”。 悉尼大学副校长（研究）emma johnston教授对这笔资金表示欢迎，这笔资金将推动比恩科走向商业化。 比恩科加入了悉尼大学其他成功的生物医学企业的行列，如kinoxis theraputics，一家开发一流疗法的生物技术公司，以满足对神经和精神疾病中物质使用障碍和社会功能障碍的有效治疗日益增长的需求；以及弹性蛋白，一家由悉尼大学麦考分校于2005年成立的公司ey生物化学主席，教授anthonyweiss-am，制造一种名为原弹性蛋白的蛋白质来治疗严重烧伤和慢性伤口。 “这笔mrff赠款将支持bienco将其业务商业化，并帮助每年需要角膜移植的数千名澳大利亚人。 ”。university of sydney-led bienco consortium has received $35 million from the australian government to commercialise their world-leading research into treatments for corneal blindness.artificial cornea specimen developed by the bienco consortium. image credit: stefanie zingsheim, university of sydneythe australian government has awarded $35 million to bienco, a group of researchers leading the charge against corneal blindness which affects an estimated 23 million people worldwide. bienco is a world-first consortium of clinical, scientific and governance experts from the university of sydney, university of wollongong, university of melbourne, queensland university of technology (qut), the centre for eye research australia, and the nsw organ & tissue donation service (otds). it is developing a bioengineered corneal replacement tissue by incorporating cells and tissue generously donated by deceased donors.corneal disease is the third most common form of blindness and over 10 million are on a waiting list for a corneal transplant.professor gerard sutton. image credit: stefanie zingsheim, university of sydneybienco program lead professor gerard sutton from the university of sydney said the condition has a profound impact on people’s lives and presents a significant cost to the health system.“bienco was launched in 2021 by this group of australian researchers to create corneas that will prevent people becoming needlessly blind throughout the world. thanks to our consortium partners, we’ve been able to rapidly develop word-first solutions for corneal blindness. “we believe this is the largest grant for eye research in australia’s history,” said professor sutton, corneal specialist at the university of sydneys save sight institute and previous medical director of the nsw tissue bank, otds.professor gordon wallace, an esteemed innovator, educator and scientist at the forefront of health technologies at the university of wollongong said, “this positions us as a global bioengineered tissue provider and is humbling recognition of the importance of our work, and the advancements the bienco team have made.”over 2000 australians every year require a corneal tissue transplant to restore their vision. many of these are aboriginal and torres strait islander people.“currently, these transplants are reliant on tissue donated from deceased individuals. the developing world, including many countries in africa, and southeast asia, has a chronic shortage of corneas due to a paucity of tissue banks. bienco’s foundational work has already made significant progress in creating next-generation bioengineered materials that will significantly reduce the need for donated tissue and increase the speed and quality of care patients receive,” said professor mark daniell, head of corneal research at cera.the qut bienco node, led by professor damien harkin, will provide critical expertise in methods for the isolation, cultivation and validation of donor corneal cells. “at present, there is only one donor cornea available globally to treat every 70 people requiring a corneal transplant. through laboratory cultivation we estimate that a single donor cornea could provide treatment for 30 people” said professor harkin. image credit: stefanie zingsheim, university of sydneydanielle fisher, general manager of the nsw organ and tissue donation service said severe vision impairment and blindness has profound impacts, including on reduced quality of life, medical costs, costs of long-term care and costs due to lost productivity.“restoring sight not only benefits an individual person, it benefits their family and community,” ms fisher said. “it allows them to go back to their work, studies, and the community activities that they enjoy. it also reduces the burden on those caring for them. the bienco bioengineered products will create health economic benefits, in part by creating better patient outcomes.”professor greg qiao, who will lead the university of melbourne node focusing on the synthetic substrates for the project, said, “our ultimate goal is to develop the technology to produce many grafts from one donors’ tissue, to help alleviate the global shortage of donor corneas.”minister mark butler announced the grant today, saying, “this facility is a major step towards ensuring there is help available for those who need it. these revolutionary treatments prove once again that australian medical researchers are among the best in the world.”university of sydney vice-chancellor and president, professor mark scott ao, added that the funding is welcome recognition of the university of sydney’s strategy for translational research with global impact.“corneal blindness is a global challenge, especially for our near neighbours in south-east asia. this mrff grant is welcome acknowledgement of the our commitment to research that tackles some of the world’s biggest problems and contributes to the common good, which underpins our 2032 strategy,” said professor scott.university of sydney deputy vice-chancellor (research) professor emma johnston welcomed the funding, which will propel bienco to commercialisation.“bienco joins the likes of other successful university of sydney biomedical ventures such as kinoxis therapeutics, a biotechnology company developing first in class therapeutics to address the growing need for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders; and elastagen, a company founded in 2005 by university of sydney mccaughey chair of biochemistry, professor anthony weiss am, to manufacture a protein called tropoelastin to treat severe burns and chronic wounds.“this mrff grant will support bienco in commercialising its operations and help the thousands of australians who need a corneal transplant every year.”.本文来源： 3500万美元用于改变人生的角膜失明研究
亲，点击此处在线申请留学咨询服务和报名评估！我们将竭诚提供最佳评估服务！
